Publication at First Faculty of Medicine |
2015
Abstract
Cardiovascular (CV) prevention remains a top priority not only in our country. Despite a significant decrease of CV mortality the Czech Republic remains a country with a high CV mortality rate.
There are more reasons, low attainment of treatment targets being the most important. Options for reduction of atherothrombotic complication risk have widened over recent years.
Brand new approaches in the treatment of dyslipidemia including PCSK9 inhibition or therapies utilizing anti-sense technologies rapidly have emerged. We have already learned about their lipid-modifying efficacy but also the first evidence regarding their impact on the risk of vascular events.